Actively Recruiting
Randomized Study of BBT001 Drug and Placebo to Evaluate Safety and Effects in Healthy Adults and Patients With Moderate to Severe Atopic Dermatitis
Led by Bambusa Therapeutics · Updated on 2026-09-29
237
Participants Needed
14
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating BBT001, a drug candidate being developed for atopic dermatitis, in a Phase 1, randomized, double-blinded, placebo-controlled study. The study includes both healthy volunteers and adults with moderate to severe atopic dermatitis to assess safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamics, and preliminary clinical activity. The study has several parts single ascending dose SAD and multiple ascending dose MAD phases. Healthy volunteers will receive either a single or multiple doses of BBT001 or placebo, while patients with atopic dermatitis will receive multiple doses of BBT001 or placebo. These doses are administered under controlled conditions to compare effects and monitor responses. Participants will undergo safety monitoring through adverse event recording, blood tests, vital sign checks, physical exams, and ECG readings for up to 169 days following the first dose. Researchers will measure drug levels and immune responses to BBT001, as well as clinical activity related to atopic dermatitis. The study duration varies by part but involves multiple visits for assessments and monitoring.
CONDITIONS
Brief Title
A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)
Research Team
L
Lisa Li
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here